Literature DB >> 24862758

Antitumor immunity induced after α irradiation.

Jean-Baptiste Gorin1, Jérémie Ménager1, Sébastien Gouard1, Catherine Maurel1, Yannick Guilloux1, Alain Faivre-Chauvet2, Alfred Morgenstern3, Frank Bruchertseifer3, Michel Chérel4, François Davodeau1, Joëlle Gaschet5.   

Abstract

Radioimmunotherapy (RIT) is a therapeutic modality that allows delivering of ionizing radiation directly to targeted cancer cells. Conventional RIT uses β-emitting radioisotopes, but recently, a growing interest has emerged for the clinical development of α particles. α emitters are ideal for killing isolated or small clusters of tumor cells, thanks to their specific characteristics (high linear energy transfer and short path in the tissue), and their effect is less dependent on dose rate, tissue oxygenation, or cell cycle status than γ and X rays. Several studies have been performed to describe α emitter radiobiology and cell death mechanisms induced after α irradiation. But so far, no investigation has been undertaken to analyze the impact of α particles on the immune system, when several studies have shown that external irradiation, using γ and X rays, can foster an antitumor immune response. Therefore, we decided to evaluate the immunogenicity of murine adenocarcinoma MC-38 after bismuth-213 ((213)Bi) irradiation using a vaccination approach. In vivo studies performed in immunocompetent C57Bl/6 mice induced a protective antitumor response that is mediated by tumor-specific T cells. The molecular mechanisms potentially involved in the activation of adaptative immunity were also investigated by in vitro studies. We observed that (213)Bi-treated MC-38 cells release "danger signals" and activate dendritic cells. Our results demonstrate that α irradiation can stimulate adaptive immunity, elicits an efficient antitumor protection, and therefore is an immunogenic cell death inducer, which provides an attractive complement to its direct cytolytic effect on tumor cells.
Copyright © 2014 Neoplasia Press, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24862758      PMCID: PMC4094834          DOI: 10.1016/j.neo.2014.04.002

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  47 in total

1.  Survival of human lung epithelial cells following in vitro alpha-particle irradiation with absolute determination of the number of alpha-particle traversals of individual cells.

Authors:  C Søyland; S P Hassfjell
Journal:  Int J Radiat Biol       Date:  2000-10       Impact factor: 2.694

2.  Alpha particles induce apoptosis through the sphingomyelin pathway.

Authors:  Jonathan H Seideman; Branka Stancevic; Jimmy A Rotolo; Michael R McDevitt; Roger W Howell; Richard N Kolesnick; David A Scheinberg
Journal:  Radiat Res       Date:  2011-06-01       Impact factor: 2.841

Review 3.  Is there a common mechanism underlying genomic instability, bystander effects and other nontargeted effects of exposure to ionizing radiation?

Authors:  William F Morgan
Journal:  Oncogene       Date:  2003-10-13       Impact factor: 9.867

Review 4.  Radiation-induced bystander effects--implications for cancer.

Authors:  Carmel Mothersill; Colin B Seymour
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

5.  Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines.

Authors:  Stephane Supiot; Sebastien Gouard; Josiane Charrier; Christos Apostolidis; Jean-Francois Chatal; Jacques Barbet; François Davodeau; Michel Cherel
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

6.  Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer.

Authors:  Hiroki Kuniyasu; Naohide Oue; Atsuko Wakikawa; Hideo Shigeishi; Norimasa Matsutani; Kazuya Kuraoka; Reiko Ito; Hiroshi Yokozaki; Wataru Yasui
Journal:  J Pathol       Date:  2002-02       Impact factor: 7.996

7.  (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Mol Cancer Ther       Date:  2012-01-11       Impact factor: 6.261

Review 8.  Radiolabeled antibodies for cancer imaging and therapy.

Authors:  Jacques Barbet; Manuel Bardiès; Mickael Bourgeois; Jean-François Chatal; Michel Chérel; François Davodeau; Alain Faivre-Chauvet; Jean-François Gestin; Françoise Kraeber-Bodéré
Journal:  Methods Mol Biol       Date:  2012

9.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

10.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Authors:  Eric A Reits; James W Hodge; Carla A Herberts; Tom A Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin Camphausen; Rosalie M Luiten; Arnold H de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques J Neefjes
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

View more
  26 in total

1.  Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.

Authors:  Julia Fazel; Silvia Rötzer; Christof Seidl; Benedikt Feuerecker; Michael Autenrieth; Gregor Weirich; Frank Bruchertseifer; Alfred Morgenstern; Reingard Senekowitsch-Schmidtke
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

Review 2.  Immunogenic cell death in cancer and infectious disease.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2016-10-17       Impact factor: 53.106

Review 3.  α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1.

Authors:  Sophie Poty; Lynn C Francesconi; Michael R McDevitt; Michael J Morris; Jason S Lewis
Journal:  J Nucl Med       Date:  2018-03-15       Impact factor: 10.057

Review 4.  Combining Heavy-Ion Therapy with Immunotherapy: An Update on Recent Developments.

Authors:  Alexander Helm; Daniel K Ebner; Walter Tinganelli; Palma Simoniello; Alessandra Bisio; Valentina Marchesano; Marco Durante; Shigeru Yamada; Takashi Shimokawa
Journal:  Int J Part Ther       Date:  2018-09-21

Review 5.  Using immunotherapy to boost the abscopal effect.

Authors:  Wilfred Ngwa; Omoruyi Credit Irabor; Jonathan D Schoenfeld; Jürgen Hesser; Sandra Demaria; Silvia C Formenti
Journal:  Nat Rev Cancer       Date:  2018-02-16       Impact factor: 60.716

6.  Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model.

Authors:  Hing-Yuen Yeung; Pui-Chi Lo; Dennis K P Ng; Wing-Ping Fong
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

Review 7.  Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection.

Authors:  Lukas M Carter; Sophie Poty; Sai Kiran Sharma; Jason S Lewis
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-30       Impact factor: 1.921

8.  Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study.

Authors:  Michael E Autenrieth; Christof Seidl; Frank Bruchertseifer; Thomas Horn; Florian Kurtz; Benedikt Feuerecker; Calogero D'Alessandria; Christian Pfob; Stephan Nekolla; Christos Apostolidis; Saed Mirzadeh; Jürgen E Gschwend; Markus Schwaiger; Klemens Scheidhauer; Alfred Morgenstern
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-11       Impact factor: 9.236

Review 9.  Consensus guidelines for the detection of immunogenic cell death.

Authors:  Oliver Kepp; Laura Senovilla; Ilio Vitale; Erika Vacchelli; Sandy Adjemian; Patrizia Agostinis; Lionel Apetoh; Fernando Aranda; Vincenzo Barnaba; Norma Bloy; Laura Bracci; Karine Breckpot; David Brough; Aitziber Buqué; Maria G Castro; Mara Cirone; Maria I Colombo; Isabelle Cremer; Sandra Demaria; Luciana Dini; Aristides G Eliopoulos; Alberto Faggioni; Silvia C Formenti; Jitka Fučíková; Lucia Gabriele; Udo S Gaipl; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Nathalia A Giese; Zong Sheng Guo; Akseli Hemminki; Martin Herrmann; James W Hodge; Stefan Holdenrieder; Jamie Honeychurch; Hong-Min Hu; Xing Huang; Tim M Illidge; Koji Kono; Mladen Korbelik; Dmitri V Krysko; Sherene Loi; Pedro R Lowenstein; Enrico Lugli; Yuting Ma; Frank Madeo; Angelo A Manfredi; Isabelle Martins; Domenico Mavilio; Laurie Menger; Nicolò Merendino; Michael Michaud; Gregoire Mignot; Karen L Mossman; Gabriele Multhoff; Rudolf Oehler; Fabio Palombo; Theocharis Panaretakis; Jonathan Pol; Enrico Proietti; Jean-Ehrland Ricci; Chiara Riganti; Patrizia Rovere-Querini; Anna Rubartelli; Antonella Sistigu; Mark J Smyth; Juergen Sonnemann; Radek Spisek; John Stagg; Abdul Qader Sukkurwala; Eric Tartour; Andrew Thorburn; Stephen H Thorne; Peter Vandenabeele; Francesca Velotti; Samuel T Workenhe; Haining Yang; Wei-Xing Zong; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

10.  Immune radiobiology.

Authors:  Claire Vanpouille-Box
Journal:  J Transl Med       Date:  2021-06-10       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.